louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06665451: Erythropoietin Gel Effect on Dental Implant Stability
Official title: Evaluation of Erythropoietin Gel Effect on Stability of Immediate Implant ( Clinical and Radiographical Study )
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Osseointegration
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-10-30
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * Achieving and maintaining long-term osseointegration for dental implants is a key objective in the field of dentistry. The success of osseointegration is influenced by the surface treatment applied to dental implants. Numerous coating techniques have been developed to improve and speed up osseointegration.
* The aim of the current study is to assess immediate dental implant stability coated with erythropoietin gel, both clinically and radiographically.
* Materials and Methods: We conducted a randomized controlled clinical trial.The sample will include patients demanding immediate implant treatment in the anterior maxilla . Patients will be randomly allocated into the two groups of the study. The group A will be treated with erythropoietin gel coated dental implant immediately after extraction of non restorable teeth in the anterior maxilla . Group B will be treated with non coated dental implant immediately after extraction of non restorable teeth in the anterior maxilla .
* The primary outcome variable will be implant stability and the secondary outcome will be crestal marginal bone level and bone density around implants. It will be measured at time of implant placement and reevaluated after 6-months .


Eligibility criteria: Inclusion Criteria:

* All patients Should have nonrestorable teeth in the anterior maxilla indicated for extraction and seeking implant placement.
* Good general periodontal health and maintenance.

Exclusion Criteria:

* Heavy smokers who smoke more than ten cigarettes per day
* Acute infected socket
* Ant socket with wall defect.
* Pregnency
* Local or systemic conditions that will interfere with bone healing (uncontrolled diabetes mellitus or human immune deficiency virus infections, resonance therapy), bone disorders (hyperparathyroidism, osteoporosis, or Paget's disease.
* Patients who had subjected to intravenous and/or oral bisphosphonate therapy.

Primary outcomes:
measure: Change in implant stability
timeFrame: Baseline and after 6 month
Secondary outcomes:
measure: Change in marginal bone level and bone density around implants
timeFrame: Baseline and after 6 month
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Faculty of dental medicine Al-Azhar university
Study officials:
affiliation: faculty of Dental medicine Al-Azhar University
name: Mohamed Alaa Lecturer of OMFS
role: STUDY_DIRECTOR
References:
Clinical trial NCT06657651: IMMEDIATE IMPLANT With Different Types of Membranes
Official title: Autogenous Dentine Derived Barrier Membrane Versus Extended Platelet Rich Fibrin Membrane in Immediate Implant Placement
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Tooth Extraction
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-10-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: forty patients will be selected from the outpatient's clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University for replacement of non-restorable tooth in posterior mandibular area.

Patients' Grouping:

The patients will be randomly divided into two equal uniform groups each consists of 20 patients:

Group A:

20 patients with non-restorable mandibular molar tooth will be treated with an immediately placed dental implant in conjunction with a dentin-derived membrane from the extracted tooth.

Group B:

20 patients with non-restorable mandibular molar tooth will be treated with an immediately placed dental implant in conjunction with extended platelet rich fibrin membrane.


Eligibility criteria: Inclusion Criteria:

* Age above 18 years
* Non-restorable mandibular molar tooth that needs dental extraction \& guided bone regeneration for immediate implant placement.
* Acceptable inter-arch space for the future prosthesis.
* Patient medically free from systemic diseases that absolutely contraindicate implant surgery.
* Cooperative patient with high motivation and acceptable oral hygiene.
* Free from history of bruxism / parafunctional habits.

Exclusion Criteria:

* Local and / or systemic conditions that interfere with the procedure.
* Smokers.
* Pregnancy.
* Uncooperative patients.
* Patient had undergone in the past 12 months radiation therapy to the head and neck area.

Primary outcomes:
measure: Implant stability
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Heba Elsheikh
Study officials:
References:
Clinical trial NCT02242851: Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
Official title: Pharmaco-epidemiological Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-17
Enrollment: 5018
Sex: ALL
Minimum age (years): 21
Maximum age (years): 94
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hypertensive patients treated with Telmisartan for at least one month recruited by ceneral practitioners and cardiologists

Brief summary: Primary objective: to characterize hypertensive patients treated for at least 1 month with Telmisartan (alone or in combination with other drugs) in order to define the beneficiary population (those actually receiving the treatment).

Secondary objectives:

* to describe the patients' blood pressure values (when self-monitored) and satisfaction with the treatment (ease of use, efficacy, safety) on the basis of a patient self-questionnaire, filled out 4 weeks after consultation.
* to compare the characteristics of the beneficiary population to those of the initial target population defined in the SPC (summary of product characteristics) for Telmisartan


Eligibility criteria: Inclusion Criteria:

* Hypertensive patients treated with Telmisartan for at least one month, consulting a medical practitioner (for whatever reason)

Exclusion Criteria:

Primary outcomes:
measure: Characteristics of hypertensive patients
timeFrame: Baseline, after 1 month of treatment
Secondary outcomes:
measure: Changes in blood pressure
timeFrame: Up to 1 month
measure: Evaluation of patients satisfaction with treatment
timeFrame: Up to 1 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02400177: Parents Workgroup About Emotion Regulation
Official title: Parenting Workshop on Emotion Regulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autism Spectrum Disorders
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2015-03-26
Enrollment: 96
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is examine emotional regulation and reflective functioning in parents of children with Autism Spectrum Disorders (ASD) before and after an educational training (four sessions of group workshops). Our experimental aims are the following: 1) examine parental emotion regulation and reflective functioning in daily life, 2) examine child emotion regulation in their daily life 3)Learn about the training efficacy for ASD parents. This research study will help to formulate innovative treatment methods to reinforce positive emotion regulation and reflective functioning in both ASD children and their parents.

Detailed description: The parents will answer questionnaires and Parent Development Interview (PDI) and the Five Minute Free Speech Sample (FMSS) as well as a number of other questionnaires.

Parents will be randomized between intervention group and control group. First session

* Introduction
* Setting expectations and goals
* General explanation of emotions and their development.
* How to recognize emotions? Why is it important to recognize them?
* Minding parents and child emotions. Second session
* Emotion Regulation (general explanation).
* Strategic for emotion regulation (Adults)
* Strategic for emotion regulation (children)
* Parental emotion regulation and the influence on the child emotion regulation
* Difficulties in ER among children with ASD Third session
* Three steps method: Feel, Think-Rethink, Regulate.
* Theory, explanation and implementation.
* Discussion: Role play of challenging highly affective parent-child interaction

Fourth session:

* Three steps method: Feel, Think-Rethink, Regulate.
* Theory, explanation and implementation.
* Discussion: Role play of challenging highly affective parent-child interaction The parents will do another PDI and will fill up the questionnaires

Eligibility criteria: Inclusion Criteria:

* Parents of children with autism ages 3-18

Exclusion Criteria:

* If they cant understand English they can not be part of the study.

Primary outcomes:
measure: Mentalization level
timeFrame: 1 month - 2 months
Secondary outcomes:
measure: Relationship coherence level
timeFrame: 1 month - 2 months
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Antonio Hardan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02415777: Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Fatigue
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2015-04-14
Enrollment: 168
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 'URSA SOFT CAP. (UDCA-003)' in fatigue patients with liver dysfunction


Eligibility criteria: Inclusion Criteria:

* CIS greater than or equal to 76, HADS less than or equal to 10
* ALT greater than upper limit of normal OR fatty liver on US

Exclusion Criteria:

* Subjects who have diseases that can cause fatigue
* Subjects who are taking medication that can cause fatigue

Primary outcomes:
measure: Rate of subjects whose CIS score has improved under 76 at week 8
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ilsan
country: Korea, Republic of
facility: Ilsan Paik Hospital
state: Kyung-gi-do
Study officials:
References:
citation: Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract. 2016 Apr;70(4):302-11. doi: 10.1111/ijcp.12790. Epub 2016 Mar 20.
Clinical trial NCT01045577: A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
Official title: A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Psoriasis
Keywords: Severe Psoriasis
Kinase Inhibitor
Masitinib
Lead sponsor: AB Science
Sponsor class: INDUSTRY
First posted: 2010-01-11
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

Detailed description: To evaluate the activity of oral AB1010, administered at two dose levels during 12 weeks to patients with moderate to severe chronic plaque psoriasis, assessed on :

i)Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), Overall Lesion Severity (OLS), Physician's Global Assessment (PGA) and Patient's Global Psoriasis Assessment (PGPA) ii)clinical and biological safety parameters iii) pharmacokinetic profile of AB1010

Eligibility criteria: Inclusion Criteria:

* Male or female outpatients aged 18 to 75 years with chronic plaque psoriasis
* Plaque psoriasis covering ≥ 10% BSA
* Disease duration ≥ 6 months
* PASI ≥ 12.0 at screening

Exclusion Criteria:

* Guttate, erythrodermic or pustular psoriasis as sole or predominant form of the disease
* Clinically significant psoriasis flare during screening or at time of enrollment
* Systemic therapy for psoriasis or systemic immunosuppressive therapy for other indications within 28 days prior to enrollment
* Topical treatment for psoriasis within 14 days prior to enrollment
* Use of CYP3A4 moderate and strong inhibitors within 4 weeks prior to randomization
* Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection

Primary outcomes:
measure: Change from baseline in BSA after 12 weeks of treatment
timeFrame: 12 weeks
Secondary outcomes:
measure: Percentage change from baseline in PASI score, proportion of patients reaching a 90%, 75% or 50% improvement in PASI score after 12 weeks of treatment; time to and duration of first occurrence in PASI 50, 75 and 90
timeFrame: 12 weeks
measure: Proportion of patients achieving an OLS rating of Minimal or Clear after 12 weeks
timeFrame: 12 weeks
measure: Percentage change from baseline in PGA and PGPA after 12 weeks of treatment
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: CHU NICE
name: Jean-Paul ORTONNE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03392077: Digital Cervical and Cesarean Section
Official title: The Role of Digital Cervical Opening in Elective Cesarean Section
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Caesarean Section
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-01-05
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women who will subjected to elective Cesarean section

Brief summary: Cesarean delivery is one of the most commonly performed surgical operations worldwide Cesarean delivery even as an elective procedure has been associated with considerable maternal risks compared with vaginal delivery. Some of the complications include postpartum hemorrhage, uterine infection, urinary tract infection, wound infection, septicemia and maternal death. Over the years, many variations in the surgical technique of Cesarean delivery have been employed with the main purpose of improving its safety. A woman's cervix is firm and undilated at the beginning of pregnancy, but progressive remodeling occurs during gestation until the cervix is soft at term, especially the nulliparous cervix . The progressive dilatation of the cervix needs uterine contraction during labor. A mechanical dilatation of the cervix at cesarean section is defined as an artificial dilatation of the cervix performed by finger, sponge forceps or other instruments at non-labor cesarean section. According to a cochrane view The information currently available about the advantages of cervical dilatation at cesarean section is inconclusive. This may be due to small sample sizes and low power of statistic.


Eligibility criteria: Inclusion Criteria:

1. All women scheduled for elective cesarean section will be approached.
2. Women accepted to participate in the study participation after discussing the nature of the study.

Exclusion Criteria:

1. Immuno-compromised women.
2. Women suffering from any coagulation disorder or Blood disease.
3. Blood transfusion during surgery or before it.
4. History of wound infection or endometritis .
5. Ante partum hemorrhage.
6. History of long corticosteroid use.
7. Women refuse to participate in the study.
8. Suspected clinical evidence of infection.
9. anemic women
10. Multiple pregnancy
11. Preterm births
12. Rupture of membranes or chorioamnionitis
13. Women who use antibiotics during the last 24 hours due to any infection but not prophylactic antibiotic during caesarian section
14. Emergency caesarean section

Primary outcomes:
measure: The amount of postpartum blood loss (ml)
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Woman's Health Hospital
Study officials:
References:
Clinical trial NCT04000477: Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening Smear
Official title: Endocervical Curettage Performed With a Kevorkian Curette Versus Cytobrush in Patients With ASC-H, LSIL, ASCUS HPV Positive and Non-contributory Colposcopy (ZT3) Smear or Atypical Pap Smear With Positive HPV Test
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cervical Cancer
Pathological Screening Smear
Keywords: Endocervical curettage
Kevorkian
Cytobrush
FCV
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2019-06-27
Enrollment: 588
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The recommendations on the method and the realization of the cervico-uterine smears are clear. With regard to performing endocervical curettage, several methods are possible without precise consensus. In general, the Kevorkian curette is widely used. However, it is often reported by doctors and patients that curettage is painful. Some articles show that the cytobrush would be less painful. While keeping a percentage of correct curettage failures, it is sought to show that the cytobrush would improve the comfort of the patient during curettage.


Eligibility criteria: Inclusion Criteria:

* Women followed for a cervical pathology requiring endocervical curettage:
* AGC type (glandular cell atypia) with positive HPV test
* Frottis ASC-H, LSIL, ASCUS HPV + with non-contributive colposcopy (ZT3)

Exclusion Criteria:

* Pregnant woman
* Women under the age of 25 or over 65
* Stenosis of the neck complete or tight not allowing the possible insertion of a curette (inadequate size cervical orifice and material)
* Presence of a vaginal lesion on colposcopic examination

Primary outcomes:
measure: Percentage of sampling failures
timeFrame: once time, Baseline
Secondary outcomes:
measure: Pain Assessment Using a Visual Analogue Scale (VAS)
timeFrame: once time, Baseline
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Lille
name: Sophie Jonard, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05739877: Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State
Official title: An Open Label, Randomized, Single Dose, Cross-over ,Two-group Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-02-22
Enrollment: 34
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(2.5/500 mg x1 tablets) at fed state


Eligibility criteria: Inclusion Criteria:

* Healthy Volunteers
* BMI between 18 and 30 kg/m2
* Body weight : Male≥50kg, Female≥45kg

Exclusion Criteria:

* Allergy or Drug hypersensitivity
* Clinically significant Medical History

Primary outcomes:
measure: AUCt
timeFrame: pre-dose~48 hours post-dose
measure: Cmax
timeFrame: pre-dose~48 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Anyang-si
country: Korea, Republic of
facility: Metro Hospital
state: Gyeonggi-do
Study officials:
References:
Clinical trial NCT01236677: The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing
Official title: The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Community Acquired Pneumonia
Keywords: Pathogen
Lead sponsor: Capital Medical University
Sponsor class: OTHER
First posted: 2010-11-09
Enrollment: 1100
Sex: ALL
Minimum age (years): 14
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Confirmed community acquired pneumonia

Brief summary: In the 21st century, threats to human health of new respiratory infectious diseases increased.

The project aim is to establish pneumonia pathogens network in Beijing and understand the pathogen spectrum distribution.


Eligibility criteria: Inclusion Criteria:

1. Confirmed community acquired pneumonia
2. Age≥14 ys
3. New appear of cough or cough become severe
4. New infiltration showed by chest radiology(x-ray or CT)
5. Fever T\>37.8o C or \<35.6o C
6. White blood cell\>10,000/mm3 , left shift or leukopenia\<4000/ul）

Exclusion Criteria:

1. Pregnancy or breast-feeding
2. Over one week after the onset of symptoms
3. HIV infection
4. Recent 90-day hospitalized history(length of stay greater than 2 days)
5. Live in nursing homes or rehabilitation hospitals

Primary outcomes:
measure: Time to resolution of all symptoms (defined as the period from start of study-drug to relief of fever)
timeFrame: one year
Secondary outcomes:
measure: If duration of symptoms long, follow-up 30 days.
timeFrame: one year
measure: In case of early termination:death;diagnosed tuberculosis;diagnosed lung cancer and HIV infection
timeFrame: one year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute
state: Beijing
Study officials:
affiliation: Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute
name: Chen Wang, Doctor
role: STUDY_CHAIR
References: